Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SRZN vs SGMO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SRZN Captures Overall Composite Edge (32.8 SELL vs 52.0 HOLD), While SGMO Leads 3–2 on Growth & Valuation Pillars

SRZN Overall Winner 6-Pillar Tally: SRZN 2 – 3 SGMO (1 Tie) Matrix Metrics: SRZN 5 – 4 SGMO

As of Nov 16, 2026, Surrozen, Inc. Common (SRZN) captures the overall head-to-head institutional edge over Sangamo Therapeutics, Inc. (SGMO) on higher Unified Composite conviction (32.8/100 SELL vs. 52.0/100 HOLD) after splitting the core matrix 5–4 (led by Growth & Scale, Balance Sheet & Cash Flow), while SGMO wins 3–2 across the 6-pillar growth and valuation breakdown. SRZN trades at $32.94 (N/M Forward P/E, -485.4% operating margin) versus SGMO at $0.18 (0.4x Forward P/E, -175.5% operating margin).

  • Composite vs. Pillar Nuance: While SGMO currently prints a higher short-term Unified Composite Score (52.0/100 HOLD vs. SRZN 32.8/100 SELL), SRZN captures the overall institutional head-to-head verdict (5–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. -175.5% operating margin) and revenue trajectory (+408.6% vs. +88.4% YoY).
  • Technical & Structure Timing Caution: SRZN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 62.9); meanwhile SGMO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SRZN vs SGMO
SRZN NASDAQ Head-to-Head Winner
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$32.94
+4.21% 1D
Market Cap $603.7M
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.21β · 62% Vol
Unified Composite Score
32.8 / 100 SELL
Tech 50.0 Fund 32.0 Flow 64.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (10.1% over 20 days), RSI 63
RSI-14: 62.9 · SMA20: $29.54 · SMA50: $26.11
SGMO NASDAQ
Sangamo Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.18
+31.56% 1D
Market Cap $55.9M
TTM Revenue $40M
Forward P/E 0.4x
Beta / 30D Vol 1.49β · 206% Vol
Unified Composite Score
52.0 / 100 HOLD
Tech 25.0 Fund 46.0 Flow 65.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.4%), weak momentum, RSI 38
RSI-14: 38.4 · SMA20: $0.23 · SMA50: $0.31

6-Pillar Scorecard Institutional Category Breakdown (SRZN 2 – 3 SGMO)

Columns: Metric · SRZN · SGMO
1. Valuation Multiples SGMO
Forward P/E N/M 0.4x
Trailing P/E N/M 0.4x
PEG Ratio N/M N/M
EV / Revenue 48.4x 1.2x
2. Growth & Scale SRZN
Revenue Growth (YoY) +408.6% +88.4%
Earnings Growth (YoY) -37.0% +0.0%
TTM Revenue (USD) $11M $40M
Market Cap $603.7M $55.9M
3. Profitability & Quality SGMO
Gross Margin N/A N/A
Operating Margin -485.4% -175.5%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -62.8% -2891.8%
4. Balance Sheet & Cash Flow SRZN
Cash Generation (TTM) -$31M -$90M
Cash Flow Margin N/A N/A
Net Cash / Leverage $95M Net Cash $8.3M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SGMO
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 72.0% (5th %ile) 144.2% (71st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SRZN (5) vs SGMO (4)
Institutional Metric SRZN SGMO Criterion Row Edge
Market Capitalization
Scale
$603.7M $55.9M Larger Scale SRZN
Trailing P/E Ratio
Valuation
N/M 0.4x Lower Multiple SGMO
Forward P/E Ratio
Valuation
N/M 0.4x Lower Multiple SGMO
Revenue Growth (YoY)
Growth
+408.6% +88.4% Higher Growth SRZN
Operating Margin (TTM)
Profitability
-485.4% -175.5% Higher Margin SGMO
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-62.8% -2891.8% Higher ROE SRZN
52-Week Range Position
Momentum
81% ($12–$38) 9% ($0–$1) Stronger Trend SRZN
Beta / 30D Volatility
Risk Regime
1.21β · 62% Vol 1.49β · 206% Vol Lower Realized Risk SRZN
Unified Institutional Score
Composite Signal
32.8 / 100 (SELL) 52.0 / 100 (HOLD) Higher Composite SGMO
Trailing 12M Revenue (USD)
Operating Scale
$11M $40M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 48.4x EV/Rev N/M PEG · 1.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$31M ($95M Net Cash) -$90M ($8.3M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SRZN +55.89 pp
SRZN: +15.07% · SGMO: -40.82%
3M Horizon SRZN +113.84 pp
SRZN: +45.11% · SGMO: -68.73%
6M Horizon SRZN +225.06 pp
SRZN: +164.6% · SGMO: -60.46%
1Y Horizon SRZN +225.06 pp
SRZN: +164.6% · SGMO: -60.46%

Financial Trajectory Annualized Quarterly Run-Rate Revenue & Operating Margin Trajectory (USD-Normalized)

Split-Invariant USD Revenue & Operating Margin (%)
Period SRZN Revenue SGMO Revenue SRZN Op. Margin SGMO Op. Margin Margin Leader
Q3 '25 $0M $0M -1107.3% -6119.3% SRZN
Q4 '25 $0M $60M -2393.8% -175.5% SGMO
Q1 '26 $20M $10M -209.1% -2215.4% SRZN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SRZN CONSOLIDATION
37d in phase · OBV NEUTRAL
Current IV 72.0%
IV Percentile 5th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact SRZN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SGMO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 144.2%
IV Percentile 71st %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SGMO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SRZN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $603.7M market capitalization and -485.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SGMO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $55.9M market capitalization and -175.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SRZN vs SGMO Key Questions & Quantitative Answers

As of Nov 16, 2026, Surrozen, Inc. Common (SRZN) captures the overall head-to-head institutional edge over Sangamo Therapeutics, Inc. (SGMO) on higher Unified Composite conviction (32.8/100 SELL vs. 52.0/100 HOLD) after splitting the core matrix 5–4 (led by Growth & Scale, Balance Sheet & Cash Flow), while SGMO wins 3–2 across the 6-pillar growth and valuation breakdown. SRZN trades at $32.94 (N/M Forward P/E, -485.4% operating margin) versus SGMO at $0.18 (0.4x Forward P/E, -175.5% operating margin). Composite vs. Pillar Nuance: While SGMO currently prints a higher short-term Unified Composite Score (52.0/100 HOLD vs. SRZN 32.8/100 SELL), SRZN captures the overall institutional head-to-head verdict (5–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. -175.5% operating margin) and revenue trajectory (+408.6% vs. +88.4% YoY). Technical & Structure Timing Caution: SRZN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 62.9); meanwhile SGMO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SRZN leads the Growth & Scale pillar: SRZN posts +408.6% YoY revenue growth and -37.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -485.4% operating margin), compared with SGMO at +88.4% YoY revenue growth and +0.0% YoY earnings growth on $40M TTM revenue (N/A gross margin, -175.5% operating margin). Across the 3-period historical trajectory (Q3 '25 to Q1 '26), SRZN cumulative revenue shifted N/A while SGMO shifted -83.3%. In operating R&D and SG&A reinvestment, SRZN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SGMO.

SGMO screens cheaper on headline valuation multiples. SRZN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 48.4x EV/Revenue (unreported FCF margin), whereas SGMO trades at 0.4x Forward P/E, 0.4x Trailing P/E, N/M PEG, and 1.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SRZN (-62.8% ROE) versus SGMO (-2891.8% ROE) capital efficiency.

In options market volatility and institutional positioning, SRZN carries 72.0% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.21β · 62% Vol realized risk). By comparison, SGMO carries 144.2% implied volatility (71st %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.49β · 206% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.